BICO Group AB (publ) (CLLKF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BICO Group AB (publ) (CLLKF) with AI Score 47/100 (Weak). BICO Group AB (publ) operates as a bio convergence company, providing laboratory solutions and bioautomation products to medical, pharmaceutical, and cosmetic industries. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026BICO Group AB (publ) (CLLKF) Healthcare & Pipeline Overview
BICO Group AB, a bio convergence company, provides laboratory solutions and bioautomation products, including 3D bioprinters and single-cell dispensing instruments, to the medical, pharmaceutical, and cosmetic sectors. Operating globally, BICO serves diverse industries with its advanced tissue engineering and diagnostics solutions, facing competition in a dynamic market.
Investment Thesis
BICO Group AB (publ) presents a compelling, albeit high-risk, investment thesis centered on its innovative bio convergence solutions. With a market capitalization of $0.14 billion and a negative P/E ratio of -1.11, the company's financial performance reflects its growth stage. Key value drivers include the increasing adoption of 3D bioprinting and bioautomation technologies in the pharmaceutical and cosmetic industries. Growth catalysts include expanding into new geographic markets and developing advanced applications for its core technologies. However, the company's negative profit margin of -70.2% and high beta of 2.77 indicate significant volatility and financial challenges. Investors should closely monitor BICO's ability to improve profitability and manage its operational costs to capitalize on its technological advancements. The company's success hinges on its ability to translate innovative products into sustainable revenue streams.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.14B reflects BICO's valuation in the bio convergence market.
- P/E Ratio of -1.11 indicates the company is currently not profitable, common for growth-stage companies.
- Profit Margin of -70.2% highlights the challenges in achieving profitability despite revenue generation.
- Gross Margin of 45.3% demonstrates the potential for profitability as the company scales and optimizes its operations.
- Beta of 2.77 suggests the stock is highly volatile compared to the market.
Competitors & Peers
Strengths
- Innovative bioprinting technology.
- Strong presence in the laboratory solutions market.
- Diversified product portfolio.
- Global operations.
Weaknesses
- Negative profit margin.
- High beta indicating high stock volatility.
- Dependence on R&D for future growth.
- Limited financial resources.
Catalysts
- Ongoing: Continued expansion into personalized medicine applications, driving revenue growth.
- Ongoing: Development and launch of advanced bioinks with enhanced biocompatibility.
- Upcoming: Potential strategic acquisitions and partnerships to expand product portfolio (within 1-2 years).
- Ongoing: Geographic expansion into emerging markets, increasing global market share.
- Ongoing: Integration of AI and machine learning into bioprinting processes, improving efficiency and capabilities.
Risks
- Potential: Intense competition in the bioprinting market could erode market share.
- Ongoing: Stringent regulatory requirements may delay product approvals and increase compliance costs.
- Potential: Technological obsolescence could render current products and services outdated.
- Potential: Economic downturns could reduce R&D spending and affect demand for bioprinting solutions.
- Ongoing: Negative profit margin and high beta indicate financial instability and stock volatility.
Growth Opportunities
- Expansion into Personalized Medicine: BICO has the opportunity to leverage its 3D bioprinting technology to create personalized medical solutions. The market for personalized medicine is projected to reach $2.4 billion by 2028, driven by advancements in genomics and diagnostics. BICO can develop patient-specific tissues and organs for transplantation, offering a significant competitive advantage. This expansion requires strategic partnerships with hospitals and research institutions and is expected to generate revenue within the next 3-5 years.
- Development of Advanced Bioinks: The bioink market is crucial for the success of 3D bioprinting. BICO can invest in developing advanced bioinks with enhanced biocompatibility and mechanical properties. The global bioink market is expected to reach $273.8 million by 2027. By creating bioinks that support the growth and differentiation of various cell types, BICO can improve the quality and functionality of bioprinted tissues and organs. This initiative requires significant R&D investment and collaboration with materials science experts and is expected to yield results in 2-4 years.
- Strategic Acquisitions and Partnerships: BICO can pursue strategic acquisitions and partnerships to expand its product portfolio and market reach. The bio convergence industry is highly fragmented, offering opportunities to acquire complementary technologies and expertise. By acquiring companies specializing in areas such as microfluidics, genomics, and cell line development, BICO can strengthen its position as a comprehensive solutions provider. These activities can be executed within the next 1-2 years and will contribute to long-term growth and market leadership.
- Geographic Expansion into Emerging Markets: BICO can expand its presence in emerging markets, such as Asia-Pacific and Latin America, where demand for advanced healthcare technologies is growing rapidly. These markets offer significant growth potential due to increasing healthcare expenditure and a growing awareness of the benefits of bio convergence technologies. BICO can establish local sales and distribution networks, as well as partnerships with local research institutions and hospitals. This expansion is expected to occur over the next 3-5 years and will contribute to revenue diversification and global market share.
- Integration of AI and Machine Learning: BICO can integrate artificial intelligence (AI) and machine learning (ML) into its products and services to enhance their capabilities and improve efficiency. AI and ML can be used to optimize bioprinting processes, analyze large datasets, and develop predictive models for tissue engineering. This integration will enable BICO to offer more advanced and personalized solutions to its customers. The implementation of AI and ML technologies is expected to take place over the next 2-3 years and will provide a competitive edge in the market.
Opportunities
- Expansion into personalized medicine.
- Development of advanced bioinks.
- Strategic acquisitions and partnerships.
- Geographic expansion into emerging markets.
Threats
- Intense competition in the bioprinting market.
- Stringent regulatory requirements.
- Technological obsolescence.
- Economic downturns affecting R&D spending.
Competitive Advantages
- Proprietary bioprinting technology protected by patents.
- Strong brand reputation in the bioprinting market.
- Established relationships with key customers in the pharmaceutical and biotechnology industries.
- Expertise in developing and manufacturing bioinks and reagents.
About CLLKF
BICO Group AB (publ), formerly known as Cellink AB (publ), was founded in 2016 and rebranded in August 2021 to reflect its broader bio convergence strategy. Headquartered in Gothenburg, Sweden, BICO operates globally, serving North America, Europe, Asia, and other international markets. The company functions through two primary segments: Laboratory Solutions and Bioautomation. The Laboratory Solutions segment offers a range of products including 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and liquid handling instruments. It also provides services and related consumables, such as bioinks, reagents, microscope lenses, software, printheads, and 3D reconstructed human tissues, which are used in regulatory testing. This segment extends its services to pharmaceutical and biotechnology companies, offering expertise in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology. The Bioautomation segment focuses on precision dispensing and biosensor technology for industrial customers, as well as diagnostics automation and advanced robotics solutions for the medical and diagnostic industries. BICO's offerings also include core industrial ecosystem, tissue engineering, multi-omics, cell line development, and diagnostics solutions. The company's primary customers are in the medical, pharmaceutical, and cosmetic industries, where its technologies are used for research, development, and manufacturing.
What They Do
- Develops and sells 3D bioprinters for creating biological tissues and organs.
- Offers hybrid microscopes for advanced imaging of cells and tissues.
- Provides single-cell dispensing instruments for precise cell manipulation.
- Manufactures liquid handling instruments for automating laboratory processes.
- Supplies bioinks and reagents for 3D bioprinting applications.
- Offers services in 3D cell culture, tissue imaging, and digital pathology.
- Provides diagnostics automation and advanced robotics solutions for medical industries.
Business Model
- Direct sales of bioprinting equipment and related consumables.
- Service contracts for maintenance and support of bioprinting systems.
- Licensing of its proprietary technologies to other companies.
- Providing research and development services to pharmaceutical and biotechnology companies.
Industry Context
BICO Group AB (publ) operates within the rapidly evolving medical devices industry, specifically focusing on bio convergence. This sector is characterized by the integration of biology, engineering, and data science to create innovative solutions for healthcare and industrial applications. The market is driven by increasing demand for personalized medicine, regenerative therapies, and advanced diagnostics. BICO competes with companies offering similar bioprinting and bioautomation technologies. The industry is also subject to stringent regulatory requirements and technological advancements, requiring continuous innovation and adaptation.
Key Customers
- Pharmaceutical companies using bioprinting for drug discovery and development.
- Biotechnology companies creating engineered tissues and organs.
- Cosmetic companies testing products on 3D reconstructed human tissues.
- Research institutions studying cell behavior and tissue engineering.
Financials
Chart & Info
BICO Group AB (publ) (CLLKF) stock price: Price data unavailable
Latest News
No recent news available for CLLKF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CLLKF.
Price Targets
Wall Street price target analysis for CLLKF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CLLKF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Maria Forss
CEO
Maria Forss is the CEO of BICO Group AB (publ), leading a team of 695 employees. Her background includes extensive experience in managing and scaling technology-driven companies. She has a proven track record in strategic leadership, business development, and operational excellence. Maria's expertise spans across various industries, including healthcare, biotechnology, and advanced materials. She is known for her ability to drive innovation and create value for shareholders.
Track Record: Under Maria Forss's leadership, BICO Group AB (publ) has focused on expanding its product portfolio and geographic reach. She has overseen the development of new bioprinting applications and the integration of AI and machine learning into the company's products. Maria has also been instrumental in forging strategic partnerships and acquisitions to strengthen BICO's position in the bio convergence market. Her tenure has been marked by a commitment to innovation and sustainable growth.
CLLKF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that BICO Group AB (publ) may not meet the minimum financial standards required for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as those listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and increased volatility. This tier is also known as the Pink Open Market.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to less stringent reporting requirements.
- Lower trading volume and liquidity compared to major exchanges.
- Potential for wider bid-ask spreads and increased price volatility.
- Higher risk of fraud or manipulation due to less regulatory oversight.
- OTC Other tier stocks may not meet minimum financial standards.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's OTC Markets disclosure status.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Company has a clear business model and revenue generation strategy.
- Company has a professional website and investor relations materials.
- Company has a management team with relevant experience.
- Company has a history of operations and financial performance.
- Company is audited by a reputable accounting firm.
Common Questions About CLLKF
What does BICO Group AB (publ) do?
BICO Group AB (publ) operates as a bio convergence company, focusing on developing and commercializing bioprinting and bioautomation technologies. The company provides 3D bioprinters, single-cell dispensing instruments, and related consumables to medical, pharmaceutical, and cosmetic industries. BICO's solutions enable researchers and manufacturers to create engineered tissues, develop new drugs, and test cosmetic products on 3D reconstructed human tissues. The company aims to revolutionize healthcare and industrial processes through its innovative bio convergence technologies.
What do analysts say about CLLKF stock?
AI analysis is currently pending for CLLKF. Generally, analysts may focus on BICO Group AB (publ)'s growth potential in the bioprinting and bioautomation markets, its financial performance, and its competitive positioning. Key valuation metrics would likely include revenue growth, gross margin, and operating expenses. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. Analyst ratings and price targets are subject to change and should be considered as one factor among many.
What are the main risks for CLLKF?
The main risks for BICO Group AB (publ) include intense competition in the bioprinting market, stringent regulatory requirements, technological obsolescence, and economic downturns affecting R&D spending. The company's negative profit margin and high beta also indicate financial instability and stock volatility. Additionally, as an OTC-listed stock, CLLKF carries risks associated with lower liquidity, limited financial disclosure, and potential for wider bid-ask spreads. Investors should carefully consider these risks before investing in CLLKF.
What are the key growth opportunities for CLLKF in healthcare?
BICO Group AB (publ) has several key growth opportunities within the healthcare sector. These include expanding into personalized medicine by creating patient-specific tissues and organs for transplantation, developing advanced bioinks with enhanced biocompatibility, and integrating AI and machine learning into its products to improve efficiency and personalization. By capitalizing on these opportunities, BICO can strengthen its position as a leading provider of bio convergence solutions in the healthcare industry. The company's ability to innovate and adapt to evolving market needs will be crucial for its long-term success.
How does BICO Group AB (publ) manage patent expiration risks?
As a company reliant on proprietary technology, BICO Group AB (publ) faces the risk of patent expirations. To mitigate this, BICO likely employs a strategy of continuous innovation, developing new technologies and applications to maintain a competitive edge. They may also seek to extend patent protection through incremental improvements and new patent filings. Strategic partnerships and acquisitions can also provide access to new technologies and intellectual property, diversifying the company's portfolio and reducing its reliance on any single patent. Monitoring the competitive landscape and proactively addressing potential patent challenges is also crucial.
What are the key factors to evaluate for CLLKF?
BICO Group AB (publ) (CLLKF) currently holds an AI score of 47/100, indicating low score. Key strength: Innovative bioprinting technology.. Primary risk to monitor: Potential: Intense competition in the bioprinting market could erode market share.. This is not financial advice.
How frequently does CLLKF data refresh on this page?
CLLKF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CLLKF's recent stock price performance?
Recent price movement in BICO Group AB (publ) (CLLKF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative bioprinting technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for CLLKF may provide further insights.
- OTC market investments carry higher risks.